Contract Clinical Research Organization Market Size and Trends

The Global Contract Clinical Research Organization Market is estimated to be valued at USD 80.10 Bn in 2024 and is expected to reach USD 149.21 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 9.3% from 2024 to 2031.

Key Takeaways of the Global Contract Clinical Research Organization Market:

The clinical trial service segment is expected to contribute the highest share of the market with 42.1% in 2024.
The oncology segment is expected to contribute the highest share of the market with 37.1% in 2024.
The pharmaceutical company’s segment is expected to contribute the highest share of the market with 40.3% in 2024.
North America is expected to top the market with 37.3% of the market share, followed by Asia Pacific with 28.7% of the market share in 2024.

Market Overview:

There is an increase in research and development activities in the pharmaceutical and biotechnology industry. Moreover, outsourcing of clinical trials and research activities help companies reduce costs and improve efficiency. Research organizations provide high quality research services to various sponsors which is also driving the market growth. However, lack of skilled workforce and strict regulatory requirements associated with clinical trials may hamper the market growth during the forecast period.

Contract Clinical Research Organization Market Concentration By Players

To learn more about this report, Request sample copy

Key Developments:

In June 2024, QPS Holdings, LLC, a global contract research organization (CRO), announced new clinical research operations leadership. This move aims to align its global medical affairs, regulatory affairs, data services, and clinical operations with its Phase I clinics, enhancing agility and efficiency to meet the evolving demands of drug development.
In February 2024, Ergomed Group, a leading provider of clinical research and pharmacovigilance services, expanded its U.S. footprint by opening a new office in Massachusetts, U.S.
In February 2024, Charles River Laboratories, a premier provider of preclinical and clinical laboratory services, partnered with Wheeler Bio, a biomanufacturing company, to accelerate the transition from therapeutic discovery to manufacturing for its clients.
In January 2024, WuXi Biologics, a global leader in biologics R&D and manufacturing, announced a collaboration with BioNTech SE, a biotechnology company, to identify investigational monoclonal antibodies for next-generation therapeutic development
In December 2021, Thermo Fisher Scientific Inc., a global leader in scientific instrumentation and research services, completed the acquisition of Pharmaceutical Product Development, LLC, a global contract research organization (CRO) strengthening its service portfolio and capabilities

Top Strategies Followed by Global Contract Clinical Research Organization Market Players

Established Players: Leading CRO companies extensively focus on research and development to innovate high-quality and cost-effective solutions.
- For example, IQVIA invests over 10% of its annual revenue into R&D to develop advanced technologies like artificial intelligence platforms and real-world data solutions. Parexel allocates significant funds to expand its laboratory and biorepository networks.
Mid-Level Players: Mid-sized CROs focus on delivering value through affordable yet reliable offerings. PRA Health Sciences provides streamlined solutions at competitive prices targeting small biotech companies and startups.
- Medpace offers both full-service and customizable a la carte solutions, catering to cost-sensitive customers without compromising on quality. Icon focuses on functional service outsourcing and standardized processes to keep costs low.
Small-Scale Players: Boutique CROs target specialized therapeutic areas or services where they can establish expertise.
- For example, Clintec focuses exclusively on oncology trials. SynteractHCR concentrates on decentralized and virtual trials. EsgeeClinical specializes in rare disease patient recruitment. By developing deep niche expertise, small players grow competitive in targeted domains.

Emerging Startups - Global Contract Clinical Research Organization Industry Ecosystem

Innovative Technologies: Companies like Science 37 use digital technologies for virtual and hybrid trials. NoviSci focuses on predictive biomarkers through machine learning applications. Clinicea applies artificial intelligence to extract insights from medical images. These startups bring novel solutions that could transform clinical research models and operations.
Sustainable Solutions: Certain startups focus on sustainability, such as Greenpharma, with its reusable packaging alternatives. ClinMonista promotes eco-friendly monitoring devices and Telehealth. Trialtx develops technologies that enhance trial diversity and participation. These startups contribute to improving the industry's sustainability performance and social impact.
Market Contribution: Startups frequently collaborate to leverage their strengths. For instance, Valo Health partners with Ology Bioservices to combine drug discovery and development expertise, while EQRx collaborates with AI startup, Anthropic, to create more affordable medicines. These partnerships enable shared knowledge and innovation, addressing unmet market needs effectively.